Pulmonary blastoma with renal metastasis responds to sorafenib.

Abstract

Biphasic pulmonary blastoma is a rare malignancy of the lung composed of proliferating epithelial and mesenchymal cells with a high vessel density at the tumor periphery. We report a rare case of renal metastasis of biphasic pulmonary blastoma that responded to sorafenib, an oral multikinase inhibitor. After 2 months of treatment with sorafenib, the renal tumor size decreased sufficiently to allow a safe laparoscopic radical nephrectomy. We believe that further studies are warranted to confirm the possible effects of sorafenib on pulmonary blastomas.

• Authors: Keerthi Mulamalla, Alexander M Truskinovsky, Arkadiusz Z Dudek
• Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 2 Issue 4 Pg. 344-7 (Apr 2007) ISSN: 1556-1380 [Electronic] United States
• PMID: 17409808 (Publication Type: Case Reports, Journal Article)

Chemical References

• Benzenesulfonates
• Phenylurea Compounds
• Pyridines
• Niacinamide
• Sorafenib

Topics

• Administration, Oral
• Adult
• Benzenesulfonates (administration & dosage)
• Biopsy, Needle
• Chemotherapy, Adjuvant
• Combined Modality Therapy
• Female
• Follow-Up Studies
• Humans
• Immunohistochemistry
• Kidney Neoplasms (drug therapy, secondary, surgery)
• Lung Neoplasms (pathology, therapy)
• Neoplasm Staging
• Nephrectomy (methods)
• Niacinamide (analogs & derivatives)
• Phenylurea Compounds
• Pneumonectomy (methods)
• Pulmonary Blastoma (pathology, secondary, therapy)
• Pyridines (administration & dosage)
• Risk Assessment
• Sorafenib
• Treatment Outcome